A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)

被引：0
|
作者：
Choueiri, T. K. [1 ]
Escudier, B. [2 ]
Powles, T. [3 ]
Cella, D. [4 ]
Lee, Y. [5 ]
Laird, D. A. [5 ]
Scheffold, C. [5 ]
Motzer, R. J. [6 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Queen Mary Univ, Barts Canc Inst, London, England
[4] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Exelixis Inc, San Francisco, CA USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [31] Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. M.
    Ramies, D. A.
    Morrissey, S.
    Lee, Y.
    Miles, D.
    Holland, J. S.
    Dutcher, J. P.
    BJU INTERNATIONAL, 2012, 109 : 4 - 4
  • [32] Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Escudier, Bernard
    Motzer, Robert J.
    Tannir, Nizar M.
    Scheffold, Christian
    Aftab, Dana T.
    Chouieri, Toni K.
    BJU INTERNATIONAL, 2016, 118 : 4 - 4
  • [33] Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT)
    Cohn, Allen Lee
    Kelley, Robin Katie
    Yang, Tsai-Shen
    Su, Wu-Chou
    Verslype, Chris
    Ramies, David A.
    Lee, Yihua
    Shen, Xiaodong
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [34] Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Tannir, Nizar M.
    Powles, Thomas
    Motzer, Robert J.
    Rolland, Frederic
    Gravis, Gwanaelle
    Staehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Cheporov, Sergey
    Gonzalez, Emilio Esteban
    Duran, Ignacio
    Larkin, James G.
    Berg, William
    Clary, Douglas O.
    Escudier, Bernard
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 129 - 130
  • [35] A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma
    Harzstark, Andrea L.
    Small, Eric J.
    Weinberg, Vivian K.
    Sun, Janine
    Ryan, Charles J.
    Lin, Amy M.
    Fong, Lawrence
    Brocks, Dion R.
    Rosenberg, Jonathan E.
    CANCER, 2011, 117 (18) : 4194 - 4200
  • [36] Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial
    Tolaney, S. M.
    Nechushtan, H.
    Berger, R.
    Kurzrock, R.
    Ron, I. G.
    Schoffski, P.
    Awada, A.
    Yasenchak, C. A.
    Burris, H. A.
    Ramies, D. A.
    Shen, X.
    Winer, E. P.
    CANCER RESEARCH, 2011, 71
  • [37] Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)
    Gordon, Michael S.
    Kluger, Harriet M.
    Shapiro, Geoffrey
    Kurzrock, Razelle
    Edelman, Gerald
    Samuel, Thomas A.
    Moussa, Ali H.
    Ramies, David A.
    Laird, A. Douglas
    Schimmoller, Frauke
    Shen, Xiaodong
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve in patients (pts) with advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Mainwaring, Paul
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
    Hellerstedt, Beth A.
    Edelman, Gerald
    Vogelzang, Nicholas J.
    Kluger, Harriet M.
    Yasenchak, Christopher A.
    Shen, Xiaodong
    Ramies, David A.
    Gordon, Michael S.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth
    Gruellich, Carsten
    Nott, Louise M.
    Cuff, Katharine
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard
    Pal, Sumanta
    Powles, Thomas
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 1 - 10
12345